GlaxoSmithKline : Q2 2021 US dollar translation PDF - 159.8KB

Income statement

Three months ended 30 June 2021

	Total	Total
	£m	$m
	----	----
TURNOVER	8,092	11,283
Cost of sales	(2,554)	(3,562)
	----	----
Gross profit	5,538	7,721
Selling, general and administration	(2,642)	(3,684)
Research and development	(1,222)	(1,704)
Royalty income	77	108
Other operating expense	(76)	(104)
	----	----
OPERATING PROFIT	1,675	2,337
Finance income	7	10
Finance expense	(192)	(268)
Loss on disposal of interests in associates	(36)	(50)
Share of after tax profits of joint ventures and associates	16	22
	----	----
PROFIT BEFORE TAXATION	1,470	2,051
Taxation	68	92
	----	----
PROFIT AFTER TAXATION	1,538	2,143
	----	----
Profit attributable to non-controlling interests	143	200
Profit attributable to shareholders	1,395	1,943
	----	----
	1,538	2,143
	----	----
EARNINGS PER SHARE	27.9p	38.8¢
	----	----
Diluted earnings per share	27.6p	38.4¢
	----	----

US dollar amounts shown above are a convenience translation of the sterling amounts. US dollar results for the six months ended 30 June 2021 are calculated using average rates for the period. US dollar results for the three months ended 30 June 2021 are calculated as the difference between these six months results translated into US dollars and US dollar results previously published for the three months ended 31 March 2021.

Income statement

Six months ended 30 June 2021

	Total	Total
	£m	$m
	----	----
TURNOVER	15,510	21,492
Cost of sales	(5,034)	(6,975)
	----	----
Gross profit	10,476	14,517
Selling, general and administration	(5,069)	(7,024)
Research and development	(2,340)	(3,243)
Royalty income	168	233
Other operating income	133	184
	----	----
OPERATING PROFIT	3,368	4,667
Finance income	17	24
Finance expense	(393)	(545)
Loss on disposal of interests in associates	(36)	(50)
Share of after tax profits of joint ventures and associates	32	44
	----	----
PROFIT BEFORE TAXATION	2,988	4,140
Taxation	(190)	(263)
	----	----
PROFIT AFTER TAXATION	2,798	3,877
	----	----
Profit attributable to non-controlling interests	330	457
Profit attributable to shareholders	2,468	3,420
	----	----
	2,798	3,877
	----	----
EARNINGS PER SHARE	49.4p	68.5¢
	----	----
Diluted earnings per share	48.9p	67.8¢
	----	----

US dollar amounts shown above are a convenience translation of the sterling amounts. US dollar results for the six months ended 30 June 2021 are calculated using average rates for the period. US dollar results for the three months ended 30 June 2021 are calculated as the difference between these six months results translated into US dollars and US dollar results previously published for the three months ended 31 March 2021.

Pharmaceuticals turnover - three months ended 30 June 2021

				Inter-				Inter-
	Total	US	Europe	national	Total	US	Europe	national
	£m	£m	£m	£m	$m	$m	$m	$m
	-----	-----	-----	-----	-----	-----	-----	-----
Respiratory	717	463	150	104	999	645	209	145
	-----	-----	-----	-----	-----	-----	-----	-----
Anoro Ellipta	134	77	36	21	187	108	50	29
Trelegy Ellipta	291	204	49	38	405	284	68	53
Nucala	292	182	65	45	407	253	91	63
HIV	1,235	716	292	227	1,721	998	407	316
	-----	-----	-----	-----	-----	-----	-----	-----
Dolutegravir products	1,189	691	280	218	1,657	962	391	304
Tivicay	407	196	72	139	567	273	101	193
Triumeq	466	292	112	62	650	406	157	87
Juluca	132	101	27	4	184	141	37	6
Dovato	184	102	69	13	256	142	96	18
Rukobia	10	10	-	-	14	14	-	-
Cabenuva	4	3	1	-	5	4	1	-
Other	32	12	11	9	45	18	15	12
Immuno-inflammation and other
specialty	233	179	17	37	324	249	24	51
	-----	-----	-----	-----	-----	-----	-----	-----
Benlysta	214	179	17	18	298	249	24	25
Sotrovimab	16	-	-	16	22	-	-	22
Oncology	119	68	49	2	166	95	68	3
	-----	-----	-----	-----	-----	-----	-----	-----
Zejula	98	54	41	3	137	75	57	5
Blenrep	21	14	8	(1)	29	20	11	(2)
Jemperli	1	-	1	-	1	-	1	-
New and Specialty Pharmaceuticals	2,304	1,426	508	370	3,211	1,987	709	515
Established Pharmaceuticals	1,925	560	455	910	2,686	781	635	1,270
	-----	-----	-----	-----	-----	-----	-----	-----
Established Respiratory	1,089	478	250	361	1,520	667	349	504
Arnuity Ellipta	10	9	-	1	14	12	-	2
Avamys/Veramyst	63	-	20	43	88	-	28	60
Flixotide/Flovent	105	68	15	22	147	95	22	30
Incruse Ellipta	53	29	19	5	74	41	26	7
Relvar/Breo Ellipta	312	153	84	75	435	213	117	105
Seretide/Advair	347	132	79	136	484	184	110	190
Ventolin	167	89	25	53	233	125	35	73
Other Respiratory	32	(2)	8	26	45	(3)	11	37
Dermatology	102	-	35	67	142	-	49	93
Augmentin	91	-	29	62	127	-	40	87
Avodart	85	-	30	55	119	1	42	76
Imigran/Imitrex	26	7	12	7	37	10	17	10
Lamictal	116	55	28	33	162	76	39	47
Seroxat/Paxil	30	-	8	22	41	-	11	30
Valtrex	23	2	9	12	32	3	12	17
Other	363	18	54	291	506	24	76	406
Pharmaceuticals	-----	-----	-----	-----	-----	-----	-----	-----
4,229	1,986	963	1,280	5,896	2,768	1,343	1,785
	-----	-----	-----	-----	-----	-----	-----	-----

Pharmaceuticals turnover - six months ended 30 June 2021

				Inter-				Inter-
	Total	US	Europe	national	Total	US	Europe	national
	£m	£m	£m	£m	$m	$m	$m	$m
	-----	-----	-----	-----	-----	-----	-----	-----
Respiratory	1,336	849	293	194	1,851	1,176	406	269
	-----	-----	-----	-----	-----	-----	-----	-----
Anoro Ellipta	251	140	72	39	348	194	100	54
Trelegy Ellipta	539	377	94	68	746	522	130	94
Nucala	546	332	127	87	757	460	176	121
HIV	2,266	1,313	579	374	3,140	1,820	802	518
	-----	-----	-----	-----	-----	-----	-----	-----
Dolutegravir products	2,179	1,267	560	352	3,019	1,755	776	488
Tivicay	708	359	147	202	981	497	204	280
Triumeq	902	548	233	121	1,250	759	323	168
Juluca	244	184	53	7	338	255	73	10
Dovato	325	176	127	22	450	244	176	30
Rukobia	17	17	-	-	24	24	-	-
Cabenuva	6	5	1	-	8	7	1	-
Other	64	24	18	22	89	34	25	30
Immuno-inflammation and other
specialty	413	324	33	56	572	449	46	77
	-----	-----	-----	-----	-----	-----	-----	-----
Benlysta	392	324	33	35	543	449	46	48
Sotrovimab	16	-	-	16	22	-	-	22
Oncology	229	133	92	4	317	184	127	6
	-----	-----	-----	-----	-----	---	-----	-----
Zejula	186	105	77	4	258	145	107	6
Blenrep	42	28	15	(1)	58	39	21	(2)
Jemperli	1	-	1	-	1	-	1	-
New and Specialty Pharmaceuticals	4,244	2,619	997	628	5,881	3,629	1,382	870
Established Pharmaceuticals	3,867	1,080	916	1,871	5,359	1,497	1,269	2,593
	-----	-----	-----	-----	-----	-----	-----	-----
Established Respiratory	2,216	920	508	788	3,071	1,275	704	1,092
Arnuity Ellipta	16	13	-	3	22	18	-	4
Avamys/Veramyst	166	-	36	130	230	-	50	180
Flixotide/Flovent	222	138	31	53	308	191	44	73
Incruse Ellipta	105	56	37	12	146	78	51	17
Relvar/Breo Ellipta	580	265	166	149	804	367	230	207
Seretide/Advair	698	249	174	275	967	345	241	381
Ventolin	356	201	50	105	493	279	69	145
Other Respiratory	73	(2)	14	61	101	(3)	19	85
Dermatology	202	-	69	133	280	-	96	184
Augmentin	182	-	52	130	252	-	72	180
Avodart	168	1	60	107	233	2	83	148
Imigran/Imitrex	51	15	24	12	71	21	33	17
Lamictal	232	110	56	66	322	152	78	92
Seroxat/Paxil	63	-	16	47	87	-	22	65
Valtrex	45	5	17	23	62	7	23	32
Other	708	29	114	565	981	40	158	783
Pharmaceuticals	-----	-----	-----	-----	-----	-----	-----	-----
8,111	3,699	1,913	2,499	11,239	5,126	2,650	3,463
	-----	-----	-----	-----	-----	-----	-----	-----

Vaccines turnover - three months ended 30 June 2021

				Inter-				Inter-
	Total	US	Europe	national	Total	US	Europe	national
	£m	£m	£m	£m	$m	$m	$m	$m
	-----	-----	-----	-----	-----	-----	-----	-----
Meningitis	225	109	96	20	314	152	134	28
	-----	-----	-----	-----	-----	-----	-----	-----
Bexsero	165	60	89	16	230	84	124	22
Menveo	59	49	5	5	82	68	7	7
Other	1	-	2	(1)	2	-	3	(1)
Influenza	33	-	-	33	46	-	-	46
	-----	-----	-----	-----	-----	-----	-----	-----
Fluarix, FluLaval	33	-	-	33	46	-	-	46
Shingles	295	237	44	14	412	331	61	20
	-----	-----	-----	-----	-----	-----	-----	-----
Shingrix	295	237	44	14	412	331	61	20
Established Vaccines	758	239	157	362	1,057	333	219	505
	-----	-----	-----	-----	-----	-----	-----	-----
Infanrix, Pediarix	136	78	27	31	190	109	38	43
Boostrix	146	66	35	45	203	92	48	63
Hepatitis	110	64	25	21	153	89	35	29
Rotarix	132	26	27	79	184	36	38	110
Synflorix	97	-	9	88	136	-	13	123
Priorix, Priorix Tetra, Varilrix	54	-	24	30	75	-	33	42
Cervarix	36	-	7	29	50	-	10	40
Other	47	5	3	39	66	7	4	55
	-----	-----	-----	-----	-----	-----	-----	-----
Vaccines excluding pandemic vaccines	1,311	585	297	429	1,829	816	414	599
Pandemic vaccines	260	211	-	49	360	292	-	68
Pandemic adjuvant	258	211	-	47	358	292	-	66
Total Vaccines	-----	-----	-----	-----	-----	-----	-----	-----
1,571	796	297	478	2,189	1,108	414	667
	-----	-----	-----	-----	-----	-----	-----	-----